Bioactive Lipid Mediators in Cardiopulmonary Pharmacology

Dr. Darryl Zeldin is a Senior Investigator and the Scientific Director at the National Institute of Environmental Health Sciences, National Institutes of Health (NIH/NIEHS). He obtained his MD degree from Indiana University School of Medicine, completed his Internship/Residency in Internal Medicine at Duke University Medical Center and his Pulmonary/Critical Care Fellowship at Vanderbilt University Medical Center. His research program focuses on understanding the role of eicosanoids in regulating pulmonary and cardiovascular function. He is a Fellow in the American College of Chest Physicians, a Fellow in the American Heart Association and is an elected member of the American Society for Clinical Investigation and American Association of Physicians. He has co-authored over 380 primary peer-reviewed articles and his work has been cited over 33,000 times. He has mentored over 85 post-baccalaureate fellows, graduate students, medical students, postdoctoral research fellows and clinical research fellows. As the NIEHS Scientific Director, he is responsible for one of the largest intramural research programs at the NIH with over 600 scientists in 11 Departments and 17 Core Facilities. Dr. John M. Seubert is a Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta. He obtained his MSc in Biological Sciences (Simon Fraser University), PhD in Pharmacology and Toxicology (University of Western Ontario) and a Postdoctoral Fellowship in Cardiovascular Pharmacology at the National Institute of Environmental Health Sciences, National Institutes of Health (NIH/NIEHS). His research program focuses on the biological role essential fatty acids have in cardiac homeostasis and pathology. A central theme involves understanding the role the cytochrome P450 system has within the cell to assist in the development novel drug targets and strategies to limit injury. He is an adjunct professor in the Department of Pharmacology, Faculty of Medicine and Dentistry at the University of Alberta. He has co-authored over 78 primary peer-reviewed articles. He has mentored over 90 undergraduate students, pharmacy students, graduate students, postdoctoral research fellows and research fellows. His research has been funded by the Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada.

Preface

Darryl C. Zeldin and John Seubert

1. Bioactive lipids in hypertension

John D. Imig

2. Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response

Mohammed A. Nayeem, Werner J. Geldenhuys and Ahmad Hanif

3. Cyclooxygenases, eicosanoids and platelets

Annalisa Bruno, Stefania Tacconelli, Annalisa Contursi, Patrizia Ballerini and Paola Patrignani

4. The roles of eicosanoids in myocardial diseases

Zuowen He and Dao Wen Wang

5. Cardioprotective mechanisms of cytochrome P450 derived oxylipins from ?-3 and ?-6 PUFAs

Christi Cho, Theresa Aliwarga, Alexandra M. Wiley and Rheem A. Totah

6. 20-Hydroxyeicosatetraenoic acid (20-HETE): Bioactions, receptors, vascular function, cardiometabolic disease and beyond

Jonathan V. Pascale, Alexandra Wolf, Yonaton Kadish, Danielle Diegisser, Melissa-Maria Kulaprathazhe, Danait Yemane, Samir Ali, Namhee Kim, David E. Baruch, Muhamad Afiq Faisal Bin Yahaya, Ercument Dirice, Adeniyi M. Adebesin, John R. Falck, Michal L. Schwartzman and Victor Garcia

7. Insights into the role of the resolvin D2-GPR18 signaling axis in cardiovascular physiology and disease

Matthew Spite and Gabrielle Fredman

8. Cytochrome P450-derived eicosanoids in brain: From basic discovery to clinical translation

Catherine M. Davis, Aseel H. Ibrahim and Nabil J. Alkayed

9. Lipid mediators generated by the cytochrome P450: Epoxide hydrolase pathway

Timo Frömel, Jiong Hu and Ingrid Fleming

10. Role of omega-3 and omega-6 endocannabinoids in cardiopulmonary pharmacology

Tiffany Y.-C. Tang, Justin S. Kim and Aditi Das

11. Oxylipins in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD)

Kimberley Cousins, Chien-Chang Chen, Esha Sehanobish and Elina Jerschow